Eli Lilly and Company (NYSE: LLY), a global healthcare leader, has released its financial results for the fourth quarter of 2023, demonstrating a remarkable period of growth and strategic advancements.
Eli Lilly’s financial performance in the fourth quarter of 2023 was nothing short of impressive. The company reported a 28% increase in revenue compared to the same quarter last year, reaching $9.35 billion.
Importantly, this growth was driven by a significant contribution from new products, including Mounjaro and Zepbound, which saw revenue soar by $2.19 billion to $2.49 billion. Growth products like Verzenio and Jardiance also performed well, contributing to a 9% increase in their revenue stream to $5.27 billion. The company’s earnings per share (EPS) on a reported basis grew by 13% to $2.42, and on a non-GAAP basis, it increased by 19% to $2.49, both inclusive of $0.62 of acquired IPR&D charges.
Eli Lilly Smashes Lofty Expectations in Q4
When compared to the expected earnings per share (EPS) of $2.31 and revenue of $8.95 billion for the quarter, Eli Lilly’s actual results exceeded market expectations. The company’s EPS of $2.49 on a non-GAAP basis surpassed the forecast, highlighting efficient operational management and a strong product portfolio. Similarly, the revenue of $9.35 billion indicated a robust demand for Lilly’s products, particularly the new and growth products, which have been critical drivers of this quarter’s performance. This outperformance reflects the company’s ability to navigate the pharmaceutical landscape adeptly, capitalizing on its innovative product lineup and strategic market positioning.
Guidance for the Future
Looking ahead, Eli Lilly provided optimistic guidance for 2024, projecting revenue in the range of $40.4 billion to $41.6 billion and EPS between $11.80 to $12.30 on a reported basis, with non-GAAP EPS expected to be between $12.20 to $12.70. This guidance anticipates continued revenue growth, largely driven by the new product lineup, albeit partially offset by expected declines in Trulicity sales. The company also plans to further invest in research and development, as well as in marketing and administrative expenses, to support the growth of its recently launched and upcoming products. Such forward-looking statements reflect Lilly’s confidence in its pipeline and its strategic focus on addressing unmet medical needs.
Disclaimer: The author does not hold or have a position in any securities discussed in the article.
The post Eli Lilly (LLY) Surpasses Expectations with $9.35 Billion in Q4 Revenue appeared first on Tokenist.
